Model-Informed Drug Development (MIDD) isn’t just a set of tools — it’s a mindset that empowers smarter, faster, and more informed decisions across every stage of drug development.

Over the course of my career in pharmacometrics, I’ve seen how quantitative approaches — especially PKPD modeling and simulation — can meaningfully shift development trajectories:

• Optimizing dosing for future trials and labels
• Predicting efficacy and safety with confidence
• Designing smarter studies and identifying key covariates
• Bridging across populations, from healthy to patient, adults to children

As I transitioned from individual contributor into leadership roles, my passion expanded beyond the science itself to include:

• Championing science communication and soft skills development within technical teams
• Guiding partners in translating clinical needs into strategic, model-informed solutions
• Mentoring and training the next generation of leaders
• Building infrastructure and implementing best practices for scalable MIDD

The future of MIDD lies not just in better models, but in better communication, strategy, process, change management, and critical thinking.  Does a gap exist in these areas in your company, your group, or yourself?

News